Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03504423
Title Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Rafael Pharmaceuticals Inc.
Indications

pancreatic adenocarcinoma

Therapies

CPI-613

CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin

Age Groups: adult | senior
Covered Countries USA | FRA | DEU | BEL


No variant requirements are available.